MARKET

SNBP

SNBP

Sun Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.500
+0.200
+6.06%
Closed 16:00 11/24 EST
OPEN
3.500
PREV CLOSE
3.300
HIGH
3.585
LOW
3.420
VOLUME
6.77K
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
2.370
MARKET CAP
33.77M
P/E (TTM)
-5.0820
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sun BioPharma EPS misses by $0.09
Sun BioPharma (SNBP): Q3 GAAP EPS of -$0.21 misses by $0.09.Cash of $10.9MPress Release
Seekingalpha · 11/12 22:01
Sun BioPharma Q3 EPS $(0.21) Misses $(0.12) Estimate
Sun BioPharma (NASDAQ:SNBP) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 75 percent.
Benzinga · 11/12 21:22
Sun BioPharma, Inc. Closes $10.5 Million Public Offering of Common Stock and Warrants
MINNEAPOLIS, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the closing of its previously announced underwritten public offering of
GlobeNewswire · 09/01 20:10
Sun Biopharma prices $10.5M equity offering
Sun BioPharma (SNBP) has priced public offering of 2,545,454 common stock and the same number of warrants at $4.125/share and warrant, for gross proceeds of ~$10.5M.Each warrant entitles the holder
Seekingalpha · 08/28 11:42
Sun BioPharma Prices ~2.545M Share Offering At $4.125 Per Share And Warrant
MINNEAPOLIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP, NASDAQ:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic
Benzinga · 08/28 11:34
IPO Update: Sun BioPharma Presents IPO Terms
Sun BioPharma has filed to raise $10 million in an IPO.The firm is developing a treatment for pancreatic cancer.SNBP is thinly capitalized and researching an area that has proven difficult for major pharmas to make much progress on.While I wish the firm well, I'll watch the IPO from the sidelines.
Seekingalpha · 08/21 17:09
Sun Biopharma names Jennifer K. Simpson as CEO
Sun BioPharma (OTCQB:SNBP) announced the appointment of Jennifer K. Simpson, Ph.D., as President and Chief Executive Officer. Dr. Simpson most recently ser
seekingalpha · 07/16 21:26
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNBP. Analyze the recent business situations of Sun Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNBP stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 5
Institutional Holdings: 340.12K
% Owned: 3.52%
Shares Outstanding: 9.65M
TypeInstitutionsShares
Increased
0
0
New
5
340.12K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chairman/Executive Director
Michael Cullen
President/Chief Executive Officer/Director
Jennifer Simpson
Vice Chairman/Lead Director/Independent Director
Jeffrey Mathiesen
Chief Financial Officer/Vice President - Finance/Secretary/IR Contact Officer
Susan Horvath
Other/Director
Suzanne Gagnon
Independent Director
Arthur Fratamico
Independent Director
Paul Schaffer
Independent Director
Donald Schemel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNBP
Sun BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company's focus is on the treatment of patients with pancreatic cancer. The Company is engaged in the commercial development of a polyamine analogue for pancreatic cancer and the second indication in chronic pancreatitis. The Company is developing SBP-101, a small molecule polyamine metabolic inhibitor delivered for the treatment of patients with pancreatic cancer and other tumor cancers. SBP-101 is a polyamine analogue that accumulates in the pancreatic acinar cells due to its chemical structure.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sun Biopharma Inc stock information, including NASDAQ:SNBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNBP stock methods without spending real money on the virtual paper trading platform.